Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 888 Show results per page	View Search Criteria \| Help With Results


1.		Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				18 and over				Pharmaceutical / Industry				104864/902 NCT00316173

Last Modified: 5/31/2007 First Published: 7/1/1999


2.		Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without SCH 58500 in Patients with Newly Diagnosed Stage III Ovarian Epithelial or Primary Peritoneal Cancer With No Greater Than 2 cm Residual Disease Following Surgery (Summary Last Modified 07/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				SPRI-C/I98-102 SPRI-C98-102, NCI-V99-1544, NCT00003880

Last Modified: 6/20/2008 First Published: 9/1/2000


3.		Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without BMS-275291 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				CAN-NCIC-BR18 BMS-CA161-003, NCT00006229, BR18

Last Modified: 3/18/2008 First Published: 4/1/2001


4.		Phase II/III Randomized Study of Gemcitabine and Carboplatin Versus Methotrexate, Carboplatin, and Vinblastine in Previously Untreated Patients With Transitional Cell Cancer of the Urothelium Who are Ineligible for Cisplatin-Based Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Other				EORTC-GU-30986 NCT00014274

Last Modified: 6/3/2008 First Published: 7/1/2001


5.		Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without Bevacizumab in Patients With Advanced, Metastatic, or Recurrent Non-Squamous Cell Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				NCI				ECOG-4599 CALGB-E4599, E4599, NCT00021060

Last Modified: 5/23/2007


6.		Phase II/III Chemotherapy with MVP (MITO/VBL/CACP) vs CHIP vs CBDCA vs VBL/CACP vs MVP-CAMP (MITO/VBL/CACP/CTX/ADR/MTX/PCB) in Patients with Metastatic (Stage III) non-Small Cell Bronchogenic Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified				NCI				EST-1583 EST-1583


7.		Phase II/III Comparison of the Platinum Compounds CBDCA vs CHIP vs CACP for Recurrent or Metastatic Epidermoid Carcinoma of the Head and Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified								UMCC-8223

Last Modified: 8/10/2007


8.		Phase III Master Protocol for Randomized Comparison of Single-agent Chemotherapy vs Standard Therapy with CAF (CTX/DOX/5-FU) in Previously Untreated Patients with Stage IV Breast Carcinoma --- Amonafide and Other Phase II Agents

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				16 to physiologic 70				NCI				CLB-8642 CALGB-8642

Last Modified: 4/12/2007


9.		Phase II Evaluation of IPP, CBDCA, CHIP, and epi-ADR as Single Agents Prior to Phase III Randomized Comparison of CECA (CACP/VP-16/CTX/ADR) vs High-Dose CACP/VP-16/CTX/ADR in Children Aged at Least 365 Days with Previously Untreated Stage D Neuroblastoma and Phase III Multimodal Treatment of Stage C Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				1 to 21				NCI				POG-8741/42 POG-8741, POG-8742, POG-8741/42

Last Modified: 11/26/2007


10.		Phase II/III Randomized Comparison of Consolidation with Intensive Chemotherapy Using CDDP/VP-16/DOX/IFF vs Myeloablative Chemoradiotherapy and Autologous Marrow Rescue and of Continuation Therapy with Isotretinoin vs No Further Therapy in High-Risk Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				0 to 18				NCI				CCG-3891 CCG-3891

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute